The tissue sample collected during the biopsy is examined and analyzed by a pathologist at the laboratory. The results are recorded in a report.
The first report, called the pathology report, includes the diagnosis of lung cancer, its type, and its stage. Sometimes, it may also mention the presence of common biomarkers like EGFR and ALK.
Later, a separate report from the pathologist provides more detailed biomarker testing results. This report, often known as a biomarker testing report, indicates whether the patient has biomarkers that suggest they may benefit from specific targeted therapies or immunotherapy drugs.
This report may take a few weeks to process. Patients should request a copy for their records. It’s helpful for discussions with their healthcare team, seeking a second opinion, or considering participation in a clinical trial.
Key points to check in the report include:
- Biomarker status: This section indicates whether specific mutations or high PD-L1 protein expression are present.
- Recommended drug or drugs: It lists the drugs that may be effective for the identified biomarkers. It is usually noted next to the biomarker status.
